RESCINDO THERAPEUTICS
Rescindo Therapeutics is a drug development firm that offers discoveries and clinical translations.
RESCINDO THERAPEUTICS
Social Links:
Industry:
Biotechnology Emergency Medicine Medical Pharmaceutical
Founded:
2015-01-01
Address:
Cary, North Carolina, United States
Country:
United States
Website Url:
http://www.rescindotherapeutics.com
Total Employee:
1+
Status:
Active
Contact:
+1-919-443-5942
Email Addresses:
[email protected]
Technology used in webpage:
Euro GoDaddy DNS GoDaddy Email Squarespace Hosted
Current Employees Featured
Official Site Inspections
http://www.rescindotherapeutics.com
- Host name: 199.59.243.227
- IP address: 199.59.243.227
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Rescindo Therapeutics"
Rescindo Therapeutics, Inc. - Drug pipelines, Patents ... - Patsnap
Explore Rescindo Therapeutics, Inc. with its drug pipeline, therapeutic area, technology platform, , Disease Domain:Nervous System Diseases, Technology Platform:ASO, AAV based gene …See details»
Rescindo’s Top Drug Candidate Gains Special FDA Designations
Feb 15, 2021 · A drug being developed by Cary-based Rescindo Therapeutics for treating a rare developmental disorder in children has received two special designations from the U.S. Food …See details»
Rescindo Therapeutics Inc - VentureRadar
Rescindo Therapeutics Inc is expediting discovery of novel therapeutic targets and drugs for human genetic disorders based in vitro cell-based and in vivo humanized zebrafish assays. …See details»
FDA Grants Rare Pediatric Disease and Orphan Drug Designations …
Feb 12, 2021 · Rescindo Therapeutics aims to discover and develop new drugs for children with rare genetic diseases using a novel approach that combines genetics, molecular biology, and …See details»
Rescindo Therapeutics - Crunchbase Company Profile & Funding
Rescindo Therapeutics is a drug development firm that offers discoveries and clinical translations.See details»
Rescindo Therapeutics - VentureRadar
Rescindo Therapeutics is drug discovery and development company focused on rare genetic diseases to improve peoples’ lives. We combine genetics, molecular biology, and high …See details»
FDA grants special designations to Cary startup’s drug that targets ...
Feb 16, 2021 · RESEARCH TRIANGLE PARK – A drug being developed by Cary-based Rescindo Therapeutics for treating a rare developmental disorder in children has received two …See details»
Rescindo Therapeutics’ RSC-57 Receives FDA Orphan Drug …
CARY, N.C., Feb 12, 2021 (SEND2PRESS NEWSWIRE) -- Rescindo Therapeutics Inc., a drug discovery company dedicated to the development of new treatments for rare genetic disorders, …See details»
RSC-57 for Kabuki Syndrome Receives Orphan Drug and Rare …
Feb 22, 2021 · Just over a week ago, drug discovery and development company Rescindo Therapeutics Inc. (“Rescindo”) shared that its drug candidate RSC-57 received both Orphan …See details»
Rescindo Therapeutics - Contacts, Employees, Board Members
Rescindo Therapeutics is a drug development firm that offers discoveries and clinical translations.See details»
Rescindo Therapeutics’ RSC-57 Receives FDA Orphan Drug …
Feb 12, 2021 · (CARY, N.C.) — NEWS: Rescindo Therapeutics Inc., a drug discovery company dedicated to the development of new treatments for rare genetic disorders, announced today …See details»
Rescindo Therapeutics’ RSC-57 Receives FDA ... - Send2Press …
CARY, N.C., Feb. 12, 2021 (SEND2PRESS NEWSWIRE) — Rescindo Therapeutics Inc., a drug discovery company dedicated to the development of new treatments for rare genetic disorders, …See details»
Rescindo Therapeutics | Drug Developments | Pipeline Prospector
Pipeline Prospector delivers free access to a database of drugs under clinical trials which made headlines done by Rescindo TherapeuticsSee details»
Rescindo Therapeutics’ RSC-57 Receives FDA Orphan Drug …
CARY, N.C., Feb. 12, 2021 -- Rescindo Therapeutics Inc., a drug discovery company dedicated to the development of new treatments for rare genetic disorders, announced today that the U.S. …See details»
Research programme: small molecule therapeutics - Rescindo …
Small molecules are being developed by Rescindo Therapeutics for the treatment of patients with neurodevelopmental disorders. Preclinical development is.See details»
Rescindo Therapeutics’ RSC-57 Receives FDA Orphan Drug …
Feb 12, 2021 · Rescindo Therapeutics Inc. was founded in 2015 by Dr. Athanasios Maroglou and Dr. Nicholas Katsanis with an objective to discover and develop new drugs for children with …See details»
Rescindo Therapeutics Revenue, Growth & Competitor Profile
Oct 21, 2024 · Rescindo Therapeutics's Annual Report & Profile shows critical firmographic facts: What is the company's size? (Annual sales and employees) What industry is the company in? …See details»
Recursion Receives FDA Clearance of Investigational New Drug ...
Jun 10, 2018 · As we embark on this important milestone of initiating our first clinical trial, we are further emboldened in our goal of building a fully integrated drug discovery and development …See details»
Repotrectinib in ROS1 Fusion–Positive Non–Small-Cell Lung Cancer
Jan 10, 2024 · Repotrectinib is a next-generation ROS1 TKI with preclinical activity against ROS1 fusion–positive cancers, including those with resistance mutations such as ROS1 G2032R. In …See details»
Research programme: Bardet-biedl syndrome therapeutics
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases. Novel small molecule therapeutics are being developed by Rescindo …See details»